Recurrent Osteosarcoma Completed Phase 2 Trials for Alisertib (DB05220)

Also known as: Osteosarcoma recurrent / Osteogenic sarcoma recurrent

IndicationStatusPhase
DBCOND0028757 (Recurrent Osteosarcoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01154816Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or LeukemiaTreatment